ARS Pharmaceuticals, Inc.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $84.3M
- Net income
- -$171.3M
- Total assets
- $327.7M
- Market cap
- $850.0M
- Operating margin
- -212.9%
- Net margin
- -203.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $84.3M
- Operating expenses
- $263.7M
- Operating income
- -$179.4M
- Income tax
- -$80.0K
- Net income
- -$171.3M
- EPS (basic)
- $-1.74
- EPS (diluted)
- $-1.74
Balance sheet
- Total assets
- $327.7M
- Current assets
- $284.9M
- Total liabilities
- $213.4M
- Current liabilities
- $39.1M
- Shareholders’ equity
- $114.3M
Cash flow
- Operating cash flow
- -$170.9M
- Investing cash flow
- $56.8M
- Financing cash flow
- $104.6M
- Net cash flow
- -$9.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $850.0M
- EPS (diluted)
- $-1.74
- Shares outstanding
- 94.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 9, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $171.3M in FY2025.
- Revenue grew 6304% from FY2022 to FY2025.
- Trading 51% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ARS Pharmaceuticals, Inc..
Write a review
News about ARS Pharmaceuticals, Inc.
News & sentiment via Polygon.io
